Voyager Therapeutics Appoints Jude Onyia as Director in Connection with Neurocrine Biosciences Collaboration
Voyager Therapeutics, Inc. has announced the appointment of Jude Onyia, Ph.D. as a director of the company, contingent upon the closing of a collaboration and license agreement with Neurocrine Biosciences, Inc. Dr. Onyia, who has served as Chief Scientific Officer of Neurocrine since November 2021, will serve on Voyager's Board of Directors until the 2024 annual meeting of the stockholders.
Key Takeaways:
- Jude Onyia, Ph.D. has been appointed as a director of Voyager Therapeutics, Inc. contingent upon the closing of a collaboration and license agreement with Neurocrine Biosciences, Inc.
- Dr. Onyia will serve on Voyager's Board of Directors until the 2024 annual meeting of the stockholders.
- He will be compensated in the same manner as Voyager's other non-employee directors, with an annual cash retainer of $40,000 and an option to purchase shares of Voyager's common stock.
- The appointment is subject to specified conditions, including Neurocrine holding less than 10% of Voyager's outstanding common stock or a change of control of the company.
- Dr. Onyia has served as Chief Scientific Officer of Neurocrine since November 2021 and has previously held roles at Eli Lilly and Company and Capsida Biotherapeutics.
- He holds a B.S. in forest biology from the State University of New York ESF Syracuse and a Ph.D. in cell and molecular biology from the SUNY Health Science Center at Syracuse.
Statistics:
- 4,395,588 shares of Voyager's common stock were issued and sold to Neurocrine in connection with the collaboration and license agreement.
- The Shares were sold at a price of $8.88 per share for an aggregate purchase price of approximately $39.0 million.
- Additionally, Voyager received an upfront payment of approximately $136.0 million from Neurocrine pursuant to the Collaboration Agreement.
Sources:
- UNITED STATES SECURITIES AND EXCHANGE COMMISSION
- FORM 8-K (Current Report) filed on February 24, 2023